Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 628.00

-2.2%

Nov 4 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (3452)	2/14/2022 8:01:30 PM
From: CuttingEdge Bio	Read Replies (1) of 3557

What they are planning to do is to show a non-inferiority result between the 12wk and 16 wk 8mg dose arms vs. the set 8-week dose Eylea 2mg arm, similar to what Roche showed for its bispecific. In the case of Roche, their faricimab arm was PRN, so the result was some percentage of patients who were able to go out to 16 weeks, some % out to 12 weeks, and showing the overall cohort still matched the outcomes with non-inferiority to the set dosing for all regimen. It is unclear to me whether Regeneron is doing PRN like that or simply having a set 12 wk arm and a set 16 wk arm on 8mg. If the latter, a win on that would be more impressive. The primary endpoint is at whatever week (48) but they'll have to show the plot over time comparing the different dose arms to really judge it.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next